MX363640B - Formulaciones y metodos para la administracion vaginal de antiprogestinas. - Google Patents

Formulaciones y metodos para la administracion vaginal de antiprogestinas.

Info

Publication number
MX363640B
MX363640B MX2014014054A MX2014014054A MX363640B MX 363640 B MX363640 B MX 363640B MX 2014014054 A MX2014014054 A MX 2014014054A MX 2014014054 A MX2014014054 A MX 2014014054A MX 363640 B MX363640 B MX 363640B
Authority
MX
Mexico
Prior art keywords
antiprogestins
methods
formulations
vaginal delivery
vaginal
Prior art date
Application number
MX2014014054A
Other languages
English (en)
Spanish (es)
Other versions
MX2014014054A (es
Inventor
S Podolski Joseph
Hsu Kuang
Original Assignee
Repros Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48614182&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX363640(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Repros Therapeutics Inc filed Critical Repros Therapeutics Inc
Publication of MX2014014054A publication Critical patent/MX2014014054A/es
Publication of MX363640B publication Critical patent/MX363640B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0034Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816Wall or shell material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2014014054A 2012-05-31 2013-05-30 Formulaciones y metodos para la administracion vaginal de antiprogestinas. MX363640B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261653674P 2012-05-31 2012-05-31
PCT/US2013/043447 WO2013181449A1 (en) 2012-05-31 2013-05-30 Formulations and methods for vaginal delivery of antiprogestins

Publications (2)

Publication Number Publication Date
MX2014014054A MX2014014054A (es) 2015-02-12
MX363640B true MX363640B (es) 2019-03-28

Family

ID=48614182

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014014054A MX363640B (es) 2012-05-31 2013-05-30 Formulaciones y metodos para la administracion vaginal de antiprogestinas.
MX2019003467A MX382986B (es) 2012-05-31 2013-05-30 El uso de una cápsula mucoadherente que comprende pululano y cdb-2914 para el tratamiento de un trastorno dependiente de la progesterona

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019003467A MX382986B (es) 2012-05-31 2013-05-30 El uso de una cápsula mucoadherente que comprende pululano y cdb-2914 para el tratamiento de un trastorno dependiente de la progesterona

Country Status (22)

Country Link
US (1) US10328022B2 (enExample)
EP (1) EP2854763B1 (enExample)
JP (1) JP6341910B2 (enExample)
KR (1) KR102127348B1 (enExample)
CN (1) CN104334158B (enExample)
AU (1) AU2013267359C1 (enExample)
BR (1) BR112014029131B1 (enExample)
CA (1) CA2872644A1 (enExample)
CL (1) CL2014003232A1 (enExample)
CO (1) CO7141411A2 (enExample)
CR (1) CR20140567A (enExample)
EA (1) EA030444B1 (enExample)
ES (1) ES2701400T3 (enExample)
IL (1) IL235450B (enExample)
IN (1) IN2014DN10548A (enExample)
MX (2) MX363640B (enExample)
NZ (1) NZ702467A (enExample)
PH (1) PH12014502516A1 (enExample)
SG (2) SG10201704858PA (enExample)
UA (1) UA114106C2 (enExample)
WO (1) WO2013181449A1 (enExample)
ZA (1) ZA201408262B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2782584B1 (en) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
EP3139908A4 (en) * 2014-05-05 2018-05-16 Repros Therapeutics Inc. Formulations and methods for vaginal delivery of antiprogestins
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11623008B2 (en) 2014-08-20 2023-04-11 Professional Compounding Centers Of America Excipient compositions for mucoadhesive pharmaceutical compositions including a synergistic combination of amylopectin, pullulan, hyaluronic acid, and xyloglucan
WO2016064873A1 (en) * 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
EP3025709B1 (en) 2014-11-27 2020-09-30 Capsugel Belgium NV Dosage form articles for external mucosal applications
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
ES3033915T3 (en) * 2017-04-14 2025-08-11 Capsugel Belgium Nv Pullulan capsules
AU2018253392B2 (en) 2017-04-14 2023-11-02 Capsugel Belgium Nv Process for making pullulan

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2377418A1 (fr) 1977-01-13 1978-08-11 Roussel Uclaf Nouveaux derives steroides 4,9-dieniques 11b-substitues, leur procede de preparation et leur application comme medicaments
FR2521565B1 (fr) 1982-02-17 1985-07-05 Dior Sa Parfums Christian Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees
FR2522328B1 (fr) 1982-03-01 1986-02-14 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments
FR2534487B1 (fr) 1982-10-15 1988-06-10 Dior Christian Parfums Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede
DE3237814A1 (de) * 1982-10-12 1984-04-12 Warner-Lambert Co., 07950 Morris Plains, N.J. Wasserfreie emulsionen und verwendung derselben
EP0501523B1 (en) 1983-11-14 1997-04-09 Columbia Laboratories, Inc. Bioadhesive compositions
FR2598421B1 (fr) 1986-05-06 1988-08-19 Roussel Uclaf Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
US5077211A (en) 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
US5468741A (en) 1993-05-28 1995-11-21 The Regents Of The University Of California Use of low levels of mifepristone to treat leiomyomata
US5543150A (en) 1993-09-15 1996-08-06 Columbia Laboratories, Inc. Method of progesterone delivery and affect thereof
IL112778A0 (en) * 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
DE4426601A1 (de) 1994-07-27 1996-02-01 Schering Ag Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri
ES2196063T3 (es) 1995-02-02 2003-12-16 Schering Ag Utilizacion de agentes antagonistas competitivos de progesterona para la preparacion de medicamentos destinados al tratamiento de hemorragias uterinas disfuncionales.
GB9522403D0 (en) * 1995-11-01 1996-01-03 Hoechst Roussel Ltd Intravaginal drug delivery device
US6900193B1 (en) 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
ATE194358T1 (de) 1996-05-01 2000-07-15 Us Gov Health & Human Serv 21-substituierte progesteron derivate als antigestagene
AU2805397A (en) 1996-08-30 1998-03-19 Population Council, Center For Biomedical Research, The Vaginal application mifepristone
US6682174B2 (en) 1998-03-25 2004-01-27 Silverbrook Research Pty Ltd Ink jet nozzle arrangement configuration
US20050070516A1 (en) 1997-10-28 2005-03-31 Vivus Inc. As-needed administration of an androgenic agent to enhance female desire and responsiveness
US6020328A (en) 1998-03-06 2000-02-01 Research Triangle Institute 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
EP1008443A1 (de) 1998-12-08 2000-06-14 Alusuisse Technology & Management AG Sterilisierbarer Folienverbund für Verpackungszwecke
US6740645B1 (en) 1999-09-03 2004-05-25 Research Triangle Institute 17β-acyl-17α-propynyl-11β-(cyclic amino) aryl steroids and their derivatives having antagonist hormonal properties
AR025609A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas
UA74168C2 (uk) 1999-10-05 2005-11-15 Коламбіа Леборетеріс (Бермуда) Лімітед Лікування ендометріозу або безпліддя, або покращення плідності та застосування бета-адренергічного агоніста для виробництва лікарського засобу
ES2546336T3 (es) * 2000-03-17 2015-09-22 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services 19-norpregnadienodiona 17-alfa-sustituida, 11-beta-sustituida-4-arilo y 21-sustituida como agentes antiprogestacionales
IN191020B (enExample) 2000-03-28 2003-09-13 Dabur Res Foundation
ES2253443T3 (es) 2000-10-18 2006-06-01 Schering Aktiengesellschaft Uso de antiprogestinas para la profilaxis y el tratamiento de enfermedades dependientes de hormonas.
JP4845165B2 (ja) 2001-07-09 2011-12-28 リプロス セラピューティクス インコーポレイテッド 男性におけるテストステロン欠損の処置のための方法および物質
CA2457526A1 (en) 2001-08-29 2003-03-13 Umd, Inc. Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy
JP2003143474A (ja) 2001-11-02 2003-05-16 Matsushita Electric Ind Co Ltd 映像信号処理システム
US7417013B2 (en) 2002-05-01 2008-08-26 Mcneil-Ppc, Inc. Warming and nonirritating lubricant compositions and method of comparing irritation
ATE461681T1 (de) 2003-04-29 2010-04-15 Gen Hospital Corp Verfahren und vorrichtungen für die verzögerte freisetzung von mehreren arzneimitteln
EP1593376A1 (en) 2004-05-04 2005-11-09 Warner-Lambert Company LLC Improved pullulan capsules
NZ552720A (en) 2004-07-09 2010-02-26 Population Council Inc Sustained release compositions containing progesterone receptor modulators
GT200500185A (es) 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
EP1865938A4 (en) 2005-03-22 2008-09-24 Repros Therapeutics Inc DOSAGE SCHEMES FOR TRANS-CLOMIPHENE
CA2604218A1 (en) 2005-04-20 2006-10-26 Pfizer Limited Pyrazole derivatives as progesterone receptor antagonists
DE102005030294A1 (de) 2005-06-24 2007-01-04 Schering Ag Nichtsteroidale Progesteronrezeptor-Modulatoren
CN101316595A (zh) * 2005-09-29 2008-12-03 利普生物药剂公司 具有改善生物利用度的包含甾族化合物衍生物和聚乙二醇化甘油酯的制剂
CN1846703A (zh) 2006-02-13 2006-10-18 程定超 米非司酮阴道给药制剂及其组成和制备方法
WO2007103510A2 (en) 2006-03-08 2007-09-13 Danco Laboratories Llc Methods, dosing regimens & medications using anti-progestational agents for the treatment of disorders
KR20070116538A (ko) * 2006-06-05 2007-12-10 유겐가이샤 코리츠 쇼지 삽입 보조 기구
JP2008012281A (ja) * 2006-06-05 2008-01-24 Koritsu Shoji:Kk 挿入補助器具
CZ300424B6 (cs) * 2006-06-20 2009-05-13 Pliva - Lachema A. S. Farmaceutická kompozice pro perorální podání
CA2673128C (en) 2006-10-24 2018-07-03 Repros Therapeutics Inc. Compositions and methods for suppressing endometrial proliferation
CA2682752C (en) 2007-04-05 2015-07-07 University Of Kansas Rapidly dissolving pharmaceutical compositions comprising pullulan
HUE029397T2 (en) 2007-04-20 2017-03-28 Preglem Sa Selective progesterone modulators for treating uterine bleeding
JP5555631B2 (ja) 2007-09-20 2014-07-23 ラピドット メディカル インポート アンド マーケティング リミテッド ミフェプリストンによる子宮平滑筋腫、平滑筋腫、筋腫、子宮類線維腫、子宮内膜症、または腺筋症を治療するための組成物および手段
TWI477276B (zh) * 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
EP2482914A1 (en) * 2009-09-29 2012-08-08 Koninklijke Philips Electronics N.V. Intrauterine electronic capsule for administering a substance
UA113283C2 (xx) 2010-12-23 2017-01-10 19-норстероїди і їх застосування для лікування прогестеронзалежних станів
WO2012121767A1 (en) 2011-03-09 2012-09-13 Arstat, Inc. Treatment of uterine fibroids by intravaginal administration of a low dose of selective progesterone receptor modulator (sprm), anti-progestin, or anti-progestational agent
UA113291C2 (xx) 2011-08-04 2017-01-10 Метаболіти транскломіфену і їх застосування

Also Published As

Publication number Publication date
US10328022B2 (en) 2019-06-25
US20150111862A1 (en) 2015-04-23
KR20150014928A (ko) 2015-02-09
MX382986B (es) 2025-03-13
CL2014003232A1 (es) 2015-03-13
CR20140567A (es) 2015-03-09
MX2014014054A (es) 2015-02-12
SG10201704858PA (en) 2017-07-28
AU2013267359C1 (en) 2016-09-29
PH12014502516B1 (en) 2015-01-12
EP2854763B1 (en) 2018-09-26
CN104334158B (zh) 2018-08-10
CN104334158A (zh) 2015-02-04
EA201492290A1 (ru) 2015-03-31
KR102127348B1 (ko) 2020-06-29
NZ702467A (en) 2016-07-29
IN2014DN10548A (enExample) 2015-08-21
MX2019003467A (es) 2019-06-06
SG11201407397WA (en) 2014-12-30
EA030444B1 (ru) 2018-08-31
ZA201408262B (en) 2015-12-23
ES2701400T3 (es) 2019-02-22
EP2854763A1 (en) 2015-04-08
HK1206622A1 (en) 2016-01-15
CA2872644A1 (en) 2013-12-05
JP6341910B2 (ja) 2018-06-13
IL235450B (en) 2020-02-27
BR112014029131A2 (pt) 2018-05-29
AU2013267359A1 (en) 2014-11-20
WO2013181449A1 (en) 2013-12-05
JP2015518052A (ja) 2015-06-25
AU2013267359B2 (en) 2016-05-26
CO7141411A2 (es) 2014-12-12
PH12014502516A1 (en) 2015-01-12
BR112014029131B1 (pt) 2021-03-09
UA114106C2 (xx) 2017-04-25
IL235450A0 (en) 2014-12-31

Similar Documents

Publication Publication Date Title
PH12014502516B1 (en) Formulations and methods for vaginal delivery of antiprogestins
PH12015501595A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015501598A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MY188450A (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015501600A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
IN2012DN06720A (enExample)
NZ702663A (en) Nuclear transport modulators and uses thereof
SG10201902429PA (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
MX2015016983A (es) Moduladores del transporte nuclear y usos de los mismos.
MX2015015589A (es) Composiciones y metodos para el suministro de agentes activos hidrófobos.
EA201491479A1 (ru) Производные лупановых тритерпеноидов и их фармацевтическое применение
PH12015500713B1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
TN2012000566A1 (en) Dry powder formulation comprising an antimuscarinic drug
MX362485B (es) Nuevos inhibidores de rock.
MY165888A (en) Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
MY175764A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
IN2014MN02269A (enExample)
BR112015027436A2 (en) Topical composition and carrier for administration of pharmaceutically or cosmetically active ingredients
MX2020005921A (es) Formulaciones y metodos para el suministro vaginal de antiprogestinas.
EA201491614A1 (ru) Способ лечения гинекологических заболеваний
MY180772A (en) Novel therapeutic mirtazapine combinations for use in pain disorders
ZA201906153B (en) Pharmaceutical compositions for combination therapy
EA201500128A1 (ru) Педиатрические жидкие композиции для перорального введения, содержащие непадутант
IN2014DN10134A (enExample)